Abstract
The aim of this study was to compare the potential of two plant lectins
peanut agglutinin (PNA) and wheat germ agglutinin (WGA), monoclonal
antibody (anti-Thy-1.2), its F(ab')(2) fragments, and galactosamine
as targeting moieties bound to the polymer drug carrier to deliver
a xenobiotic, doxorubicin, to selected cancer cell lines. We have
used primary (SW 480, HT 29) and metastatic (SW 620) human colorectal
cancer cell lines and a transfectant, genetically engineered SW 620
cell line with mouse gene Thy-1.2 (SW 620/T) to test the possibility
of marking human cancer with xenogeneic mouse gene and use it for
effective site-specific targeting. The targeting moieties and doxorubicin
were conjugated to a water-soluble copolymer based on N-(2-hydroxypropyl)methacrylamide
(HPMA) acting as a carrier responsible for controlled intracellular
release of the targeted drug. FACS analysis showed a strong binding
of WGA-FITC to all tested cell lines. Binding of PNA-FITC was considerably
weaker. The in vitro antiproliferative effect of lectin-targeted
HPMA carrier-bound doxorubicin evaluated as (3)HTdR incorporation
reflected both the intensity of the binding and the different sensitivity
of the tested cancer cells lines to doxorubicin. The antiproliferative
effect of conjugates targeted with WGA was comparable to that with
the conjugates targeted with the anti-Thy-1.2 monoclonal antibody
or their F(ab')(2) fragments. The magnitude of the cytotoxic effect
of HPMA-doxorubicin targeted with PNA was lower in all tested cell
lines. While the conjugates with WGA were more cytotoxic, the conjugates
with PNA were more specific as their binding is limited to cancer
cells and to the sites of inflammation. Noncytotoxic conjugates with
a very low concentration of doxorubicin and targeted with PNA, anti-Thy-1.2,
or their F(ab')(2) fragments exerted in some lines (SW 480, SW 620)
low mitogenic activity. The Thy-1.2 gene-transfected SW 620 metastatic
colorectal cancer cell line was sensitive to the antiproliferative
effect of Thy-1.2-targeted doxorubicin as was shown for the Thy-1.
2(+) EL4 cell line and for Thy-1.2(+) concanavalin A-stimulated mouse
T lymphocytes. These results represent the first indication of the
suitability of transfection of human cancer cells with selected targeting
genes for site-specific therapy of malignancies.
Users
Please
log in to take part in the discussion (add own reviews or comments).